Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BRAF
REST API REST API
Homo sapiens
BRAF is differentially expressed in 278 experiments: 117 organism parts: testis, blood, ... (115 more);, 154 disease states: normal, control, ... (152 more);, 88 cell types 327 cell lines 40 compound treatments and 73 other conditions.
Synonyms BRAF1
Orthologs F6U6W3_CIOIN (Ciona intestinalis)   BRAF_CHICK (Gallus gallus)   braf (Danio rerio)   Braf (Rattus norvegicus)   F1MDL4_BOVIN (Bos taurus)   Braf (Mus musculus)   phl (Drosophila melanogaster)   braf (Xenopus laevis)   Q698R1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, receptor signaling protein activity, protein binding, cytoplasm, MAP kinase kinase kinase activity, negative regulation of apoptosis, MAPKKK cascade, metal ion binding, protein tyrosine kinase activity, anti-apoptosis, membrane fraction, synaptosome, soluble fraction, activation of MAPKK activity, ATP binding, response to cAMP, small GTPase mediated signal transduction, synaptic transmission, nucleus, protein heterodimerization activity, nucleotide binding, protein serine/threonine kinase activity, signal transduction, organ morphogenesis, protein kinase activity, negative regulation of neuron apoptosis, positive regulation of peptidyl-serine phosphorylation, positive regulation of ERK1 and ERK2 cascade, response to peptide hormone stimulus, nerve growth factor receptor signaling pathway, mitogen-activated protein kinase kinase binding, protein phosphorylation, intracellular signal transduction
InterPro Term Prot_kinase_cat_dom, Raf-like_ras-bd, Prot_Kinase_C-like_PE/DAG-bd, DAG/PE-bd, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
Gene-Disease Assocation LYMPHOMA, NON-HODGKIN, FAMILIAL, CARDIOFACIOCUTANEOUS SYNDROME, LUNG CANCER, COLORECTAL CANCER; CRC, NOONAN SYNDROME 7; NS7, LEOPARD SYNDROME 3
UniProt Accession D7PBN4, P15056, Q75MQ8, E5FF37
Search EB-eye ENSG00000157764
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
Jurkat
2
E-MEXP-2197, E-GEOD-1880
BT20
2
E-MTAB-37, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-GEOD-24147, E-MTAB-37
HT1080
2
E-GEOD-20089, E-MTAB-37
321 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-360, ... (44 experiments)

Factor Value U/D Experiments
2
E-TABM-130, E-TABM-145
macrophage
1
2
E-GEOD-22373, E-GEOD-360, E-GEOD-5099
CD3- CD56bright CD62L+ NK cell
1
1
E-GEOD-21774
CD4+ T cell
1
E-MTAB-24
n/a
1
E-MTAB-24
plasma cell
1
E-MEXP-2360
82 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (60 experiments)

Factor Value U/D Experiments
control
1
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-20602, E-GEOD-16728, E-GEOD-16363 ... (5 experiments)
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
cervical carcinoma
2
E-MTAB-37, E-GEOD-5823
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
148 more value(s).


Compound treatment

studied in E-GEOD-6907, E-TABM-782, E-GEOD-5824, E-GEOD-5099, E-GEOD-15811, ... (23 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-20719, E-GEOD-412, E-MEXP-2345, E-GEOD-5824, E-MEXP-1601, ... (8 experiments)
sapphyrin PCI-2054
1
E-GEOD-6400
SDF
1
E-GEOD-7307
propofol
1
E-GEOD-4386
sapphyrin PCI-2051
1
E-GEOD-6400
M-CSF
1
E-GEOD-5099
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-MEXP-421, E-TABM-868, E-TABM-601, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-20505, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-1657, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.404 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM